Our present findings demonstrating that TP-0903 is effective in vitro and in vivo among several preclinical models of TP53 mutant AML are consistent with our previous investigation that found TP-0903 to be effective in other high-risk AML subtypes, including AML with mutations in NRAS or FLT3. Here, FLT3 is linked to acute myeloid leukemia.